Just 16 months after Johnson & Johnson scored its initial FDA app | Sixteen months after Johnson & Johnson scored its initial ...

On Monday, the U.S. Court of Appeals for the Third Circuit in Washington, D.C., ruled against Merck & Co., rejecting its ...

HHS Secretary Robert F. Kennedy Jr. has joined President Donald Trump in a renewed effort to challenge how the United States ...

Hansa has operated as a commercial-stage drugmaker since 2020, when the European Union cleared the way for imlifidase for ...

Eli Lilly is drawing attention to a lifelong journey of obesity struggles in its new campaign linked to GLP-1 Medicare access ...

With its ascent seemingly unstoppable in the last few years, automated cell therapy manufacturer Cellares is facing some ...

Daiichi Sankyo is promoting Ken Keller to lead a new globally integrated commercialization unit, putting the executive in ...

Move over, Hollywood—the real stars of the show are the ones helping patients in hospitals across the country.  | Education ...

After more than 10 years in development, Regeneron secured a landmark approval for its monoclonal antibody garetosmab, now ...

China's investigator-initiated trials, once praised for their speediness, have been drawn into scrutiny for a lack of ...

Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove its mettle as a ...

In their attempts to challenge the Medicare drug price negotiation program, introduced by former President Joe Biden under ...